BioSpace News Archive

Day Zero Diagnostics Inc. today announced it was awarded $8.2 million in additional option stage funding from CARB-X, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, a global non-profit partnership dedicated to accelerating early antibacterial research and development to address the rising global threat of drug-resistant bacteria.

Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the highlights from its early R&D Day reviewing the Company’s progress and plans for the development of its novel pipeline assets and applications of its proprietary next-generation technology platforms.

SciTech Development is pleased to announce that it has signed a $600K manufacturing agreement with The Plough Center for Sterile Drug Delivery Systems.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced two new advances in MR-only workflows to advance head and neck cancer radiotherapy imaging and simulation.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 third quarter on Thursday, November 10, 2022 before the open of the U.S. financial markets.

AbbVie (NYSE: ABBV) today announced the acquisition of DJS Antibodies Ltd (“DJS”), a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the launch of its Multiplexed Arrays Sequencing (MAS-Seq) kit in partnership with the Broad Institute of MIT and Harvard and 10x Genomics, Inc.

Medical device and technology company Lazurite™ will be one of 50 early and mid-stage device, diagnostic and digital health companies participating in the 2022 MedTech Innovator Showcase at The MedTech Conference, powered by AdvaMed, Oct. 24-26 in Boston.

Novocure (NASDAQ: NVCR) today announced a review article of anti-cancer mechanisms of action of Tumor Treating Fields (TTFields) has been published in the Journal of Molecular Cell Biology (JMCB).

Novocure announced the launch of a campaign intended to drive awareness and understanding of Tumor Treating Fields therapy as a distinct anticancer modality and an emerging cornerstone of solid tumor treatment.